Vertex CEO Defends Salary After Company Is Slammed For Orkambi Pricing At UK Hearing

 
• By Francesca Bruce

Vertex CEO Jeff Leiden has defended his company’s approach to pricing, as well as his $17m salary, at a heated UK public hearing on access to cystic fibrosis drug Orkambi.

lung illustration
Vertex CEO Defends Cystic Fibrosis Drug Pricing Strategy

More from Drug Pricing

More from Scrip